Please assess the completion status of the following clinical trial:

Trial Title: Timing of Hypertonic Saline Inhalation Relative to Airways Clearance in Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients with a documented diagnosis of CF aged ≥18 years.~2. Written informed consent.~3. At least day 10 - 14 of IV antibiotic therapy during a hospital admission for a pulmonary exacerbation.~4. Patients must be able to perform acceptable spirometric manoeuvres, according to the American Thoracic Society/ERS (ATS/ERS) standards (Miller, Hankinson et. al. 2005).~5. Patient with an FEV1% predicted of ≥ 40%predicted (Stanojevic, Wade et al. 2008).~6. Patients who are productive of sputum from screening visit to study visit 1 (≥10g over 24 hours).~7. Patients who have been prescribed HTS (Nebusal 7%) and have successfully completed a challenge test.~8. Any other chronic medication must have commenced therapy 4 weeks prior to screening and be willing to continue this therapy for the entire duration of the study.~Exclusion Criteria:~1. Day 1-9 of IV antibiotic therapy during a hospital admission.~2. Patients who are colonized with Burkholderia cepacia complex.~3. Patient who are HTS naive.~4. Patients who have an intolerance to HTS.~5. Patients who are currently participating in another study or have participated in another study with an investigational drug within one month of screening.~6. Clinically significant disease or medical condition other than CF or CF-related conditions that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.~   -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ACTs after HTS inhalation: (Type: ACTIVE_COMPARATOR): ACTs after HTS inhalation: Patients will take a bronchodilator (Salbutamol, 2 puffs) wait 15 minutes, and then take a single inhalation (4 mls) of 7% HTS (Nebusal™) via updraft nebulizer (Portex) (approximately 20 minutes) immediately followed by an airways clearance session of 10 supervised cycles of Active Cycle of Breathing Technique (ACBT) using the acapella® (approximately 20 minutes).
- ACTs during HTS inhalation (Type: ACTIVE_COMPARATOR): ACTs during HTS inhalation: Patients take a bronchodilator (Salbutamol, 2 puffs), wait 15 minutes, and then take a single inhalation (4mls) of 7% HTS (Nebusal™) through the acapella® duet (with portex updraft nebulizer attached) device. During inhalation, an airways clearance session of 10 supervised cycles of ACBT using the acapella® will be carried out (approximately 20 minutes).

Based on this trial design, predict the completion outcome and termination type (if applicable).